Initial results of the retrospective, multicenter Faricimab Real-World Evidence (FARWIDE) study, from the first 6 and 12 months of faricimab (Vabysmo; Genentech/Roche) use in eyes with wet AMD in the UK, were presented at ARVO 2024. The 21-center study included 5,804 patients (6,978 eyes); 28% were treatment naïve and 84.3% were previously treated primarily with aflibercept (Eylea; Regeneron). Reported data include: 18.4% of treatment-naive eyes (n=365) and 25.3% of previously treated eyes (n=1261) had ≥6 months of follow-up. A total of 742 eyes (24% naive) had ≥12 months of follow-up.

Treatment-naive eyes received a mean (SD) of 4.7 (0.6) and 2.0 injections in the first 6 months and 7 to 12 months of faricimab treatment, respectively, while previously treated eyes received 4.3 and 2.8 faricimab injections, suggesting a rapid extension in faricimab treatment intervals after the initial doses. The study conclusion suggested that the outcomes support the real-world durability of faricimab in treatment-naive and previously treated eyes, and that longer-term data will further clarify the potential impact of dual inhibition on disease control.